| Study | Sample Size | Tumor Type | Duration of Follow-Up | Number (%) Requiring Enucleation for Tumor Recurrence by End of Follow-Up | Number (%) Requiring Enucleation for Treatment Side Effects by End of Follow-Up | Total Number (%) Requiring Enucleation | Predictors of Requiring Enucleation after Treatment |
| Damato et al. 2005 [23] | 349 patients | Choroidal melanoma | Median 3.1 years | 8/349 (2.3%) | 17/349 (4.9%) | 25/349 (7.2%); 1.6% at 1 year, 4.0% at 2 years, 9.4% at 5 years | -- |
| Conway et al. 2006 [9] | 21 patients | Extra large choroidal or ciliochoroidal melanomas | Median 28 months | 4/21 (19.0%) | 6/21 (28.6%) | 10/21 (47.6%) | -- |
| Macdonald et al. 2011 [35] | 147 patients | Uveal melanoma | Mean 4.4 years | 48% of enucleations for suspected recurrence | 52% of enucleations for complications from proton therapy | 22.4% of patients received enucleation | -- |
| Mosci et al. 2012 [24] | 72 patients | T3 and T4 choroidal melanomas | Mean 53.4 months | -- | -- | 26% of patients received enculeation over 5 years | -- |
| Tran et al. 2012 [25] | 59 patients | Peripapillary choroidal melanoma | Median 63 months | 4/59 (6.8%) | 8/59 (13.6%) | 12/59 (20%) | -- |
| Riechardt et al. 2014 [34] | 147 patients | Peripapillary choroidal melanoma | Mean 78 months | 6/147 (4.1%) | 8/147 (5.4%) | 9.5% enucleated at 5 years, 10.7% enucleated at 10 years | -- |
| Schonfeld et al. 2014 [26] | 18 patients | Choroidal melanoma in intermediate zone of fundus | Median 77.2 months | -- | -- | 1/18 (5.6%) | -- |